Bonus Sessions at ACG Annual Meeting

ACG Annual Scientific Meeting Bonus Sessions

Add this optional package to your Annual Scientific Meeting registration for even more first-class education that provides an additional 17 hours of CME/MOC credit! This add-on provides access to dozens of recorded presentations and slides from 16 Bonus Sessions (topics listed below). These Bonus Sessions are pre-recorded narrations by faculty of their presentation slides, and will be available to watch on-demand on the ACG 2025 Conference Platform, from October until March 31, 2026. (You must register for the Annual Scientific Meeting in order to purchase the optional Annual Scientific Meeting Bonus Sessions package. Both in-person and virtual registrants can purchase this add-on package.)

In-Person "GI Ignite – Meet the Experts" Breakfast Sessions

Join ACG expert faculty at the fun and fast-paced “GI Ignite - Meet the Experts” Breakfast Sessions! Offered on Monday and Tuesday mornings for in-person attendees, these small setting events allow for heightened interaction with presenters. The first half of each 60-minute session consists of 6 expert faculty providing brief summaries and clinical pearls from their presentations. The remaining time will be devoted to Q&A and interaction with the faculty. Coffee and continental breakfast will be provided. These in-person sessions are open to all attendees, but access to the recorded lectures and slides that will be discussed requires purchase of the ACG Annual Meeting Bonus Sessions package.

Monday, October 27, 2025 | 6:45 AM - 7:45 AM (MOUNTAIN TIME)
GI IGNITE SESSION 1
Moderator: Jill K. J. Gaidos, MD, FACG
Bonus Session A: Staying One Step Ahead: Monitoring in IBD
  • Treat-to-Target: From Start to Finish
    Jill K. J. Gaidos, MD, FACG
    Illustrate a paradigm for initiating IBD therapy and discussing goals of that treatment, along with when and how to assess, and what do if the goal is not met.
  • The Pyramid Scheme: Debunking the Risks of IBD Medications
    Benjamin Click, MD, MS
    Describe the relative risks and common side effects for each class of IBD therapy.
  • Will I Be on This Forever? When Can We Consider De-escalation of Therapy in IBD?
    Erica R. Cohen, MD
    Assess the literature on de-escalation of care for patients with IBD, and review clinical scenarios where this approach could be considered.
Bonus Session B: The New Kids on the IBD Block: Treatment in 2025
  • IL-23s in IBD
    David P. Hudesman, MD, FACG
    Identify the best approach to choose between the in-class agents in Crohn’s and UC.
  • JAK Inhibitors for Moderate to Severe IBD
    Meenakshi Bewtra, MD, PhD, MPH
    Outline available in-class agents for the treatment of both moderate and severe IBD.
  • Is 2>1?: The Role of Combination Therapy in IBD
    Bruce E. Sands, MD, MS, FACG
    Evaluate the available data for when to use more than one medical therapy in IBD care.
GI IGNITE SESSION 2
Moderator: Vonda G. Reeves, MD, MBA, FACG
Bonus Session C: Building Your GI Team
  • Expanding Practice Capacity: Integrating Advanced Practice Providers (APPs) and Technology Into Your Practice
    Vonda G. Reeves, MD, MBA, FACG
    Outline methods to increase work efficiency and capacity in the office and hospital, including utilizing APPs, and the use of AI and technology for dictation of notes, endoscopy reports, patient callbacks, appointment scheduling, and more.
  • Methods of Successful Recruiting: Beyond the $$$
    Olanrewaju Y. Jimoh, MD
    Identify aspects of a job that attract employees beyond financial incentives, such as work and call schedules, vacation and family leave, ratio of clinic vs endoscopy time, and ratio of outpatient vs inpatient roles, in academic, and hospital-based or private practice.
  • Physician and APP Retention: Addressing the GI Workforce Shortage
    Steven L. Carpenter, MD, FACG
    Recognize factors that support employee retention such as compensation packages, schedule adjustment for life changes, work environment, appreciation, and non-clinical leadership roles within a practice.
Bonus Session D: Incorporating Management of Obesity Into Your Gastroenterology Practice
  • Dietary Interventions for Weight Loss: Do They Work?
    Octavia Pickett-Blakely, MD, MHS
    Identify popular diets for weight loss, including meal replacements, caloric restriction, and macronutrient and supplement recommendations, and discuss the use of online tools and websites for dietary compliance.
  • Anti-Obesity Medications (AOMs): What Is all the Hype?
    Asmeen Bhatt, MD, PhD, FACG
    Assess FDA-approved and available AOMs, drug selection algorithms, dose escalation, management of adverse events, and insurance considerations.
  • Endoscopic Bariatric and Metabolic Therapies (EBMTs): Are They Better Than Surgery?
    Allison R. Schulman, MD, MPH
    Summarize currently available primary and secondary EBMTs, training and facility requirements, outcomes, and adverse events, compared with bariatric surgery, and future directions.
GI IGNITE SESSION 3
Moderator: Harish K. Gagneja, MD, MACG
Bonus Session E: Tools and Treatments for Esophageal Motility Disorders
  • Using Old Tools in New Ways: Clinical and Endoscopic Evaluation of Dysphagia
    Anh D. Nguyen, MD
    Discuss optimization of clinical and endoscopic diagnostics of esophageal motility disorders.
  • Beyond HRM, the Gold Standard: Where Do Esophagram and EndoFLIP Fit in?
    Dustin A. Carlson, MD, MSCI
    Review available supplementary diagnostic testing to classify esophageal motility disorders after high-resolution manometry.
  • Taming the Squeeze: Treatment of Non-Achalasia Disorders
    Jennifer X. Cai, MD, MPH
    Review current evidence-based treatment of non-achalasia motility disorders.
Bonus Session F: Expanding the Horizons of Esophageal Endoscopy
  • Myotomy Made E-Z: E-POEM and Z-POEM
    Mihir S. Wagh, MD, FACG
    Describe techniques and indications for endoscopic myotomy.
  • Esophageal Interventions: Balloons, Bougies, and Stents
    Julie Yang, MD, FACG
    Differentiate available endoscopic tools for management of refractory esophageal strictures, perforations, and catastrophic bleeding.
  • It’s a Wrap! Endoscopic Anti-Reflux Interventions
    Olaya I. Brewer Gutierrez, MD
    Review indications and approved options for endoscopic treatment of GERD in patients who fail medical therapy.
GI IGNITE SESSION 4
Moderator: Jay N. Yepuri, MD, MS, FACG
Bonus Session G: Gastrointestinal Endoscopy in 2025 and Beyond
  • Creating New Pathways: EUS-Guided Drainage, Anastomosis Creation, and Beyond
    V. Raman Muthusamy, MD, MAS, FACG
    Describe how lumen-apposing stents can facilitate endoscopic therapy for gastrointestinal endoscopy.
  • A Dive Into the Third Space: Dissection and Myotomy
    Mohammad Bilal, MD, FACG
    Discuss core resection principles and plane dissection as well as the basics of endoscopic myotomy techniques.
  • Closing the Hole: Fistulas, Leaks, and Perforations
    Samuel Y. Han, MD
    Explore the various endoscopic tools and techniques available for treating endoscopic defects.
Bonus Session H: Great Debates in Endoscopy
  • Removing Large Colon Polyps: Hot or Cold?
    Hot Snare Polypectomy Is Better: Ashley L. Faulx, MD, FACG
    Cold Snare Polypectomy Is Safer: Jennifer M. Kolb, MD, MS
    Compare and contrast cautery-enhanced resection techniques with cold resection techniques.
  • Are Pancreatic Duct Stents Needed in Addition to Rectal Indomethacin in Preventing Post-ERCP Pancreatitis?
    Yes: Laith H. Jamil, MD, FACG
    No: Nalini M. Guda, MD, FACG
    Describe the effectiveness of rectal indomethacin and pancreatic duct stents alone and in combination in preventing post-ERCP pancreatitis.
Tuesday, October 28, 2025 | 7:15 AM - 8:15 AM (MOUNTAIN TIME)
GI IGNITE SESSION 5
Moderator: Jonathan A. Leighton, MD, FACG
Bonus Session I: Integrating Lifestyle and Patient: Centered Care in IBD
  • Diet and Nutrition in IBD: Practical Strategies for Patient Care
    Jana G. Al Hashash, MD, MSc, FACG
    Describe the role of specific diets in IBD management (e.g., low FODMAP, SCD), diet as therapy, and review evidence-based dietary recommendations for disease remission and symptom relief.
  • The Ripple Effect of Inflammation in IBD
    Stephanie L. Gold, MD
    Discuss the impact of obesity and metabolic complications (cardiovascular, hidradenitis suppurativa, etc.) on IBD patients.
  • Stress, Mental Health, and IBD: The Mind-Gut Connection
    Dawn B. Borromeo Beaulieu, MD, FACG
    Examine the impact of stress and mental health on IBD disease activity and review approaches to mental health screening and support in IBD care.
Bonus Session J: Utilization of Advanced Practice Providers (APPs) in Team-Based Care
  • Onboarding an APP to Your Team
    Kimberly D. Orleck, PA-C
    Illustrate a successful APP onboarding plan which encompasses education, ramp up, scope of practice, role clarity, and professional development.
  • Sub-Specialization of GI APPs
    Sarah M. Enslin, PA-C
    Discuss the role of APPs in subspecialty GI clinics including co-management of complex conditions with physicians.
  • Business Case for Adding APPs to Your Practice
    James S. Leavitt, MD, FACG
    Explain the value of adding an APP to your practice including physician time for endoscopy, revenue generation, compensation, productivity, and patient satisfaction/wait times.
GI IGNITE SESSION 6
Moderator: Renee L. Williams, MD, MHPE, FACG
Bonus Session K: Colon Poop-Pourri
  • The 2:00 am Page: Reducing GI Bleeding in the ER
    Andy Tau, MD
    Discuss management strategies for reducing GI bleeding, including diagnostic modalities and therapeutic options for therapy, as well as the roles of GI, surgery, and IR.
  • Proceed With Caution: Colonoscopy in the High-Risk Population
    Philip N. Okafor, MD, MPH, FACG
    Describe when to discontinue colonoscopy based on age or comorbidities, and how to navigate CRC screening options based on age or comorbidities.
  • Non-Invasive Screening: Does It Reduce Disparities in Cancer Outcomes?
    Renee L. Williams, MD, MHPE, FACG
    Outline the disparities in CRC screening and outcomes in under-represented and rural populations.
Bonus Session L: Pancreatic Cancer: From Detection to Palliation
  • Update on Screening for Pancreatic Cancer
    Nirav C. Thosani, MD, MHA
    Identify patients at risk for pancreatic cancer, and summarize best practices for screening.
  • Radiologic and Endoscopic Approaches to Diagnosing and Staging Pancreatic Cancer
    Jennifer Phan, MD
    Discuss the utility of endoscopic ultrasound and advanced imaging modalities in diagnosis and staging of pancreatic cancer.
  • The Role of the Endoscopist in Palliation of Symptoms Due to Pancreatic Cancer
    Viveksandeep Thoguluva Chandrasekar, MD
    Describe various endoscopic tools and techniques in palliating biliary obstruction, gastric outlet obstruction, and pain control in patients with pancreatic cancer.
GI IGNITE SESSION 7
Moderator: Brooks D. Cash, MD, FACG
Bonus Session M: Gastric Slowdown
  • Gastric Motility Disorder or DGBI?
    Gastric Motility: Michael Camilleri, MD, MACG
    DGBI: Baharak Moshiree, MD, MSc, FACG
    Recognize the complexities of the pathophysiology of gastroparesis and their impact on management considerations.
  • G-POEM for All or Hold Your Needle Knife?
    Endoscopic Management (G-POEM): John M. DeWitt, MD, FACG
    Medical Management: Amol Sharma, MD, MSc, FACG
    Critically evaluate the evidence of efficacy of endoscopic pyloromyotomy versus other existing and emerging mechanistic-based treatment strategies in the management of gastroparesis.
Bonus Session N: Anorectal Lowdown
  • London Classification: Does it Still Apply or Is the Bridge Falling Down?
    Pro: David C. Kunkel, MD
    Con: Eric D. Shah, MD, MBA, FACG
    Assess the existing London Classification of anorectal manometry and discuss the applicability to defined phenotypes of functional anorectal disorders to real-world clinical practice.
  • Biofeedback and Pelvic Floor Physical Therapy for Dyssynergic Defecation
    Swapna Gayam, MD, FACG
    Critically evaluate the evidence for the efficacy of biofeedback therapy versus pelvic floor physical therapy in the management of dyssynergic defecation.
GI IGNITE SESSION 8
Moderator: Nicole E. Rich, MD
Bonus Session O: Hot Topics in Hepatology
  • Moving the Goal Posts for Primary Biliary Cholangitis
    David W. Victor, MD, FACG
    Identify changes in new guidelines, highlight revised alkaline phosphatase target, compare newly approved therapies, and discuss expanded treatment for extrahepatic PBC manifestations.
  • Drilling Down to the Core: What to Know About Hepatitis B and Immunosuppression
    Norah A. Terrault, MD, MPH, FACG
    Discuss diagnosis of patients at risk for reactivation of hepatitis B, immunosuppression drug classes requiring hepatitis B therapy, monitoring strategies, and treatment cessation timelines.
  • Treatment to Transplantation: How to Approach Alcohol-Associated Liver Disease
    Neha Jakhete, MD
    Explain alcohol-associated hepatitis and acute-on-chronic liver failure due to alcohol, the role of transplantation in alcohol-associated hepatitis and decompensated alcohol-associated cirrhosis, scoring systems, recompensation, and management of relapse/recidivism.
Bonus Session P: Management of Liver Lesions: What to Do and Where Are We Going?
  • Liver Lesions From Incidentaloma to Carcinoma: Diagnosis and Evaluation
    Robert J. Wong, MD, MS, FACG
    Diagnose liver lesions via current ACG guidelines and algorithm, discuss the role of estrogens in liver lesion development, as well as surveillance of pre-malignant and benign liver lesions.
  • Hepatocellular Carcinoma: Resect, Transplant, or Refer?
    Nicole E. Rich, MD
    Illustrate the radiographic and radiation-based therapies for HCC, appropriate candidates for resection (specifically non-cirrhotic MASH patients), systemic oncologic therapies, and the continued role for transplantation.
  • Expanding Indications for Liver Transplantation: Colorectal Liver Metastasis and Intrahepatic Cholangiocarcinoma
    Sudha Kodali, MD
    Discuss the diagnosis of intrahepatic cholangiocarcinoma and how colorectal metastasis impacts liver transplantation decisions, based on current expanded guidelines.
View Wednesday Agenda